Ubs Group Ag Xilio Therapeutics, Inc. Transaction History

Ubs Group Ag

  • $611 Billion
  • Q3 2025

A detailed history of Ubs Group Ag transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 13,652 shares of XLO stock, worth $9,556. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,652
Previous 239,969 94.31%
Holding current value
$9,556
Previous $163,000 93.25%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025
SELL
$0.65 - $0.86 $147,106 - $194,632
-226,317 Reduced 94.31%
13,652 $11,000
Q2 2025

Aug 14, 2025
BUY
$0.65 - $1.15 $49,964 - $88,398
76,868 Added 47.13%
239,969 $163,000
Q1 2025

May 13, 2025
SELL
$0.65 - $1.48 $56,095 - $127,724
-86,300 Reduced 34.6%
163,101 $117,000
Q4 2024

Feb 14, 2025
BUY
$0.75 - $1.44 $175,251 - $336,481
233,668 Added 1485.21%
249,401 $239,000
Q3 2024

Nov 14, 2024
BUY
$0.73 - $1.02 $11,338 - $15,842
15,532 Added 7727.36%
15,733 $12,000
Q3 2022

Nov 10, 2022
SELL
$2.07 - $3.44 $5,408 - $8,988
-2,613 Reduced 92.86%
201 $1,000
Q2 2022

Aug 10, 2022
BUY
$2.08 - $7.2 $3,848 - $13,320
1,850 Added 191.91%
2,814 $9,000
Q1 2022

May 16, 2022
SELL
$6.63 - $16.05 $19,976 - $48,358
-3,013 Reduced 75.76%
964 $7,000
Q4 2021

Feb 14, 2022
BUY
$9.69 - $25.11 $38,537 - $99,862
3,977 New
3,977 $64,000

Others Institutions Holding XLO

# of Institutions
35
Shares Held
11M
Call Options Held
0
Put Options Held
0
View Full List

About Xilio Therapeutics, Inc.

XLO Quotes by TradingView
  • Ticker XLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,471,600
  • Market Cap $19.2M
  • Description
  • Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...
More about XLO
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email